Tatva Chintan Pharma rallies after Q1 PAT jumps more than two-fold
Profit before exceptional items and tax (PBT) increased 118.58% to Rs 15.41 crore in Q1 FY27 from Rs 7.05 crore in Q1 FY26. The company reported exceptional items of Rs 1.31 crore during the quarter.
EBITDA climbed 86% YoY to Rs 32.3 crore in Q1 FY27 from Rs 17.3 crore in the year-ago period. EBITDA margin improved to 19% from 15%, reflecting stronger operating performance.
During the quarter, Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC) contributed 35% of total revenue, followed by Structure Directing Agents (SDA) at 34%, Phase Transfer Catalysts (PTC) at 26%, Electrolyte Salts & Solutions (ESS) at 4%, while the remaining 1% came from other products.
Segment-wise, revenue from PASC stood at Rs 58.4 crore, SDA at Rs 57.8 crore, PTC at Rs 42.8 crore and ESS at Rs 6.3 crore during the period under review.
Meanwhile, the company's board approved a proposal to expand manufacturing capacity for various specialty chemicals at its new greenfield facility located at Dahej-III in the Dahej Industrial Estate, Bharuch, Gujarat. The expansion aims to strengthen the company's manufacturing infrastructure and cater to growing market demand.
The board also approved the re-appointment of Chintan Nitinkumar Shah as managing director for a further term of three years, from 1 February 2027 to 31 January 2030.
Additionally, the board approved a proposal to increase the company's borrowing limit to Rs 1,000 crore from the existing Rs 300 crore.
Tatva Chintan Pharma Chem is primarily engaged in manufacturing, sale and distribution of specialty chemicals, viz., phase transfer catalysts (PTC), structure directing agents (SDA), electrolyte salts and solutions (ESS), pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC).
Powered by Capital Market - Live News